| 0 (0%) | 09-27 09:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.89 | 1-year : | 33.75 |
| Resists | First : | 24.73 | Second : | 28.89 |
| Pivot price | 22.97  |
|||
| Supports | First : | 21.8 |
Second : | 19.99 |
| MAs | MA(5) : | 23.15 |
MA(20) : | 23.13 |
| MA(100) : | 19.21 |
MA(250) : | 23.57 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 41.2 |
D(3) : | 50.9 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 35.84 | Low : | 14.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CSTL ] has closed above bottom band by 43.4%. Bollinger Bands are 11.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 23.04 - 23.16 | 23.16 - 23.27 |
| Low: | 21.95 - 22.13 | 22.13 - 22.27 |
| Close: | 22.44 - 22.71 | 22.71 - 22.93 |
Wed, 24 Sep 2025
Strs Ohio Takes $366,000 Position in Castle Biosciences, Inc. $CSTL - MarketBeat
Tue, 23 Sep 2025
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award - markets.businessinsider.com
Tue, 23 Sep 2025
Diagnostic Testing Leader Castle Biosciences Secures 9th Workplace Award in 2025, Including Pittsburgh Honor - Stock Titan
Mon, 22 Sep 2025
Castle Biosciences, Inc. $CSTL Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Thu, 18 Sep 2025
Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025 - markets.businessinsider.com
Wed, 17 Sep 2025
Molecular Diagnostics Leader Castle Biosciences Recognized Among America's Top 650 Companies by Newsweek - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 29 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 93 (%) |
| Shares Short | 1,520 (K) |
| Shares Short P.Month | 1,400 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.71 |
| Profit Margin | -2.8 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | -2.8 % |
| Return on Equity (ttm) | -2.2 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 9.66 |
| Sales Per Share | 11.93 |
| EBITDA (p.s.) | 0.67 |
| Qtrly Earnings Growth | -51.6 % |
| Operating Cash Flow | 62 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | -66.8 |
| PEG Ratio | 0 |
| Price to Book value | 1.44 |
| Price to Sales | 1.9 |
| Price to Cash Flow | 10.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|